Zealand's lead drug involved in patent dispute
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7271934.ece/ALTERNATES/schema-16_9/Zealand%2520Pharma%2520bygning.jpg)
Denmark-based biotech company Zealand Pharma went out Thursday to comment on what it describes as “market speculation” concerning the active substance in the company’s GLP-1 drug Lyxumia to treat diabetes.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
He will secure the deals for Zealand Pharma
For abonnenter
Zealand to bet on niche markets
For abonnenter